Full-Time

Senior CAPA Specialist

Instruments Division

Posted on 10/1/2025

Stryker

Stryker

10,001+ employees

Manufactures orthopedic and surgical medical devices

No salary listed

Company Historically Provides H1B Sponsorship

Portage, MI, USA

Hybrid

Candidate must reside within a commutable distance to Portage, MI and is expected to be onsite multiple times/week.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Bachelor’s degree required.
  • Minimum 2 years of experience in quality systems or engineering, with exposure to CAPA processes and supporting quality system elements such as audits, management review, and quality planning.
  • Experience working in regulated environments and supporting interactions with regulatory agencies (e.g., FDA, TUV, BSI) required.
Responsibilities
  • Support post-market quality activities by reviewing and approving Nonconformances (NCs) and Corrective and Preventive Actions (CAPAs) for completeness, accuracy, and compliance with FDA, ISO 13485, and global regulatory standards.
  • Assist in developing and delivering training for CAPA users, promoting understanding of system requirements, problem-solving methodologies (e.g., 4D), and best practices.
  • Collaborate with cross-functional teams to resolve quality issues, integrate processes from acquisitions, and maintain documentation such as business process maps and SOPs.
  • Contribute to continuous improvement initiatives by assessing NC/CAPA records, identifying trends, and supporting enhancements to procedures and systems.
  • Participate in internal, corporate, and external audits by preparing documentation and supporting discussions related to NC/CAPA processes and records.
  • Monitor and present NC/CAPA metrics to leadership, helping drive achievement of key performance indicators (KPIs) and process effectiveness.
  • Facilitate CAPA boards and specialist meetings, supporting alignment across departments and ensuring timely and rigorous documentation in the eCAPA system.
  • Act as a resource for CAPA record owners and stakeholders, providing guidance on regulatory expectations, documentation standards, and system navigation.
Desired Qualifications
  • Bachelor’s degree in a Science or Engineering.
  • Working knowledge of U.S. FDA regulations and international standards (e.g., ISO 13485, EU MDR), with the ability to interpret and apply regulatory requirements in a practical setting.

Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Simplify Jobs

Simplify's Take

What believers are saying

  • Robotic surgery leadership drives double-digit sales growth through 2025.
  • India Trident II launch targets aging population's rising hip surgeries.
  • Peripheral vascular expansion via IVL meets growing arterial disease demand.

What critics are saying

  • Handala cyberattack on March 11 delays ortho supply chain 3-6 months.
  • Zimmer Biomet Persona IQ erodes ortho share with real-time analytics.
  • J&J Velys captures 25% more knee procedures from Mako in 6-12 months.

What makes Stryker unique

  • Stryker holds 39.1% US market share in orthopedic product manufacturing.
  • Trident II Acetabular System integrates Mako SmartRobotics for hip replacements.
  • Amplitude Vascular Systems acquisition adds CO₂ IVL for peripheral arteries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical & prescription plans

Supplemental health benefits

Flexible Spending accounts

Employee Assistance Program

Short-term & long-term disability

Tuition reimbursement

401(k) plan

Employee Stock Purchase Plan

Company News

ASC News
Apr 13th, 2026
ASC Technology Roundup: Distalmotion Files for Expanded Robotic Gynecology Clearance; Stryker, Medtronic Make Acquisitions

Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…

Market Wire News
Apr 13th, 2026
Stryker to acquire Amplitude Vascular Systems, adding next-gen IVL tech to peripheral vascular portfolio

Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.

Yahoo Finance
Mar 18th, 2026
Stryker posts 11% Q4 growth amid tariff pressures, margin expansion continues

Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.

Yahoo Finance
Mar 13th, 2026
Stryker shares fall 9% to $339 after Iranian cyberattack wipes 200,000+ systems

Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.

Yahoo Finance
Mar 12th, 2026
Stryker reports 11.4% revenue growth in Q4, beating estimates with $7.17B

Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.

INACTIVE